RxLabels vs Maudsley Deprescribing Guide
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
RxLabels
Access a comprehensive database of over 146,500 FDA drug labels. Search by name, company, or formulation, and instantly view detailed prescription information. Save or print labels, and explore research links to PubMed and Medline.
- Vast FDA drug label database
- Search by name, company, formulation
- Instant access to prescription labeling
- Save and print labels as PDF
- Links to PubMed and Medline articles
- Directly sourced from DailyMed
Read full descriptionHide full description
RxLabels, your go-to App for all your pharmaceutical label searches. With a vast database of over 146,500 labels submitted to the FDA, RxLabels offers an unparalleled resource for accessing drug labeling information. Search Flexibility: Look up any drug by its name, filter by company or drug formulation (tablet, capsules, suspension, injection, etc.). Find exactly what you need with ease. Instant Access: Click on any drug to view its detailed prescription labeling. All the information is right at your fingertips. Save and Print: Need to keep the information for later? Save it as a PDF or print it directly from the app. Research Links: Dive deeper into any drug with links to PubMed articles and Medline. Powered by DailyMed: Our database is directly sourced from DailyMed, ensuring up-to-date and accurate information. Whether you're a healthcare professional, a student, or just someone interested in understanding more about medicines, RxLabels provides you with the most comprehensive, user-friendly platform. The National Library of Medicine (NLM) , a National Institutes of Health (NIH) institute, provides DailyMed to the public.
Maudsley Deprescribing Guide
This app offers evidence-based guidance for healthcare professionals and interested individuals on safely discontinuing psychiatric medications. It covers antidepressants, benzodiazepines, gabapentinoids, and Z-drugs, providing principles, tapering regimens, and troubleshooting for withdrawal symptoms. The free version includes sample content, with full access available via in-app purchase.
- Evidence-based deprescribing guidelines
- Covers antidepressants, benzodiazepines, gabapentinoids, Z-drugs
- Patient-centered approach
- Distinguishes withdrawal from underlying symptoms
- Hyperbolic tapering guidance
- Step-by-step tapering regimens
- Troubleshooting withdrawal issues
Read full descriptionHide full description
"Try before you buy"-Download the FREE App,which includes sample content. In-App purchase required to unlock all content. The Maudsley Deprescribing Guidelines provide evidence-based recommendations for safely discontinuing antidepressants, benzodiazepines, gabapentinoids, and Z-drugs. This resource is essential for healthcare professionals aiming to optimize patient care and minimize medication-related harm. It emphasizes a patient-centered approach, ensuring that deprescribing is conducted thoughtfully and effectively. Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so. The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment. This evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts). Building on the recognised brand of The Maudsley Prescribing Guidelines, and the prominence of the authors’ work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as: - Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs - Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process - Distinguishing withdrawal symptoms, such as poor mood, anxiety, insomnia, and a variety of physical symptoms from symptoms of the underlying disorder that medication was intended to treat - The difference between physical dependence and addiction/substance use disorder - Explanation of why and how to implement hyperbolic tapering in clinical practice - Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches - Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual - Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse. - Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine. Disclaimer : App developers do not endorse or recommend any specific medications. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Content licensed from printed ISBN 10: 1119823021 Content licensed from printed ISBN 13: 9781119823025 If you have any questions or comments,email us any time:customersupport@skyscape.com or call 508-299-3000 Privacy Policy-https://www.skyscape.com/terms-of-service/privacypolicy.aspx Terms & Conditions-https://www.skyscape.com/terms-of-service/licenseagreement.aspx Author:Deanna Mark Horowitz; David M. Taylor Publisher:Wiley-Blackwell
Screenshots
Verdict
The clearest difference is price: Maudsley Deprescribing Guide at Free against RxLabels's $3.99. Maudsley Deprescribing Guide also leads on iOS requirement (13.0 vs 16.6). RxLabels's advantage is rating (5.0 vs 1.0) and in-app purchases (none vs 1). On ratings volume and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Maudsley Deprescribing Guide is free to download; RxLabels costs $3.99 up front. Maudsley Deprescribing Guide sells 1 one-off in-app purchase. RxLabels asks for nothing beyond the download.
RxLabels holds the better App Store score, 5.0 against 1.0. Both are backed by a comparable volume of ratings — 1 and 1 respectively.
| Parameter | RxLabels | Maudsley Deprescribing Guide |
|---|---|---|
| Price | $3.99 | Free — better |
| Rating | 5.0 (1 ratings) — better | 1.0 (1 ratings) |
| Positive reviews | — | 0.0% of reviews |
| Number of ratings | 1 | 1 |
| Update frequency | Weekly | — |
| Ads | No — better | Yes |
| In-app purchases | No — better | Yes |
| Monetization | Paid | Free with in-app purchases — better |
| Devices | iPhone, iPad | iPhone, iPad, iPod — better |
| Requires iOS | 16.6 | 13.0 — better |
| Further details — not scored | ||
| Size | 71 MB | 149 MB |
| Age rating | 17+ | 17+ |
| Developer | Vetcalculators LLC | Skyscape Medpresso Inc |
Customer experience
RxLabels
Maudsley Deprescribing Guide
In-app purchases
RxLabels
No in-app purchases
Maudsley Deprescribing Guide
- Maudsley Deprescribing Guide$48.99
Questions
Is RxLabels free?
Is Maudsley Deprescribing Guide free?
Which has better reviews, RxLabels or Maudsley Deprescribing Guide?
Do RxLabels or Maudsley Deprescribing Guide have ads?
Other comparisons















